Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
praziquantel + albendazole + amodiaquine + sulfadoxine + pyrimethamine
- Development stage
- Unknown
- Lead developer
- The London School of Hygiene & Tropical Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug combination regimen is being investigated by the London School of Hygiene and Tropical Medicine (LSHTM) for the integrated control of parasitic infections in pediatric populations. It involves the co-administration of two anthelminthic agents—praziquantel, which targets schistosomiasis by increasing calcium permeability in schistosomes, and albendazole, which targets soil-transmitted helminths by inhibiting microtubule polymerization—alongside Seasonal Malaria Chemoprevention (SMC) drugs (amodiaquine and sulfadoxine-pyrimethamine). The MALHELMIN study evaluates the safety, tolerability, and effectiveness of this integrated delivery model in Senegal, aiming to utilize the successful SMC platform to improve treatment coverage for neglected tropical diseases (NTDs) in co-endemic regions.
- Other names
- praziquantel-London School of Hygiene and Tropical Medicine-schistosomiasis-soil-transmitted helminthiasisSMC and Anthelminthic Co-administration
02
Targets
DHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))β-HematinDHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on praziquantel + albendazole + amodiaquine + sulfadoxine + pyrimethamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on praziquantel + albendazole + amodiaquine + sulfadoxine + pyrimethamine.